Design and rationale of the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry

• Published in: Respiratory investigation 2023-01, Vol.61 (1), p.95-102
• Main Authors: Okuda, Ryo, Ogura, Takashi, Hisata, Shu, Baba, Tomohisa, Kondoh, Yasuhiro, Suda, Takafumi, Johkoh, Takeshi, Iwasawa, Tae, Tomioka, Hiromi, Bando, Masashi, Azuma, Arata, Inoue, Yoshikazu, Arai, Toru, Nakamura, Yutaro, Miyamoto, Atsushi, Miyazaki, Yasunari, Chiba, Hirofumi, Ishii, Haruyuki, Hamada, Naoki, Terasaki, Yasuhiro, Kuwahira, Ichiro, Sato, Shinji, Kato, Shingo, Suzuki, Takuji, Sakamoto, Susumu, Nishioka, Yasuhiko, Hattori, Noboru, Hashimoto, Naozumi, Morita, Satoshi, Ichihara, Nao, Miyata, Hiroaki, Hagiwara, Koichi, Nukiwa, Toshihiro, Kobayashi, Kunihiko
• Format: Article
• Language: English
• Subjects: Biomarkers; Epidemiology; Humans; Idiopathic Interstitial Pneumonias - diagnosis; Idiopathic pulmonary fibrosis; Idiopathic Pulmonary Fibrosis - diagnosis; Idiopathic Pulmonary Fibrosis - epidemiology; Idiopathic Pulmonary Fibrosis - therapy; Japan; Lung; Lung Diseases, Interstitial; Progressive fibrosing interstitial lung disease; Protocol; Registries
• ISSN: 2212-5345; 2212-5353
• DOI: 10.1016/j.resinv.2022.08.009

Numerous studies investigated patients with IPF; however, only a few examined patients with idiopathic interstitial pneumonias (IIPs). The Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry, which was initiated in December 2016, is a multicenter prospective observational study of patients newly diagnosed with IIPs from 86 facilities treating ILDs. The plan is to enroll more than 600 new patients during the 2-year enrolment period and to follow their progress for 3 years after the last case enrolment. If additional consent is obtained, the study will continue for another 2 years. Research questions mainly focus on identifying the frequency by IIP classification, patient background, and diagnostic methods during enrolment, survival, acute exacerbation rate, changes in high-resolution CT imaging, forced vital capacity, and interstitial pneumonia markers over time. Other research questions, including those regarding disease behavior in patients with progressive fibrosing-ILD and new biomarkers associated with genetic predispositions, will be investigated. The JIPS Registry will provide a comprehensive description of the disease progression, prognosis, treatment status, new biomarkers, and validity of guidelines and central multidisciplinary decisions for IPF and similar diseases that can be differentiated from IPF among IIPs. Ethical approval was obtained from the institutional review board of Kanagawa Cardiovascular and Respiratory Center (KCRC-16-0005), and that of Jichi Medical University approved the biobank part (I18-005). Results will be published in peer-reviewed journals and will be presented at national and international conferences. ClinTrials.gov Registry (NCT03041623, first posted on February 3, 2017).